Kai Pharms Inc patent expiration
1. Parsabiv patent expiration
PARSABIV's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9278995 | KAI PHARMS INC | Therapeutic agents for reducing parathyroid hormone levels |
Jul, 2030
(5 years from now) | |
| US9701712 | KAI PHARMS INC | Therapeutic agents for reducing parathyroid hormone levels |
Jul, 2030
(5 years from now) | |
| US8377880 | KAI PHARMS INC | Therapeutic agents for reducing parathyroid hormone levels |
Jul, 2030
(5 years from now) | |
| US8999932 | KAI PHARMS INC | Therapeutic agents for reducing parathyroid hormone levels |
Feb, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9820938 | KAI PHARMS INC | Stable liquid formulation of AMG 416 (etelcalcetide) |
Jun, 2034
(9 years from now) | |
| US10344765 | KAI PHARMS INC | Stable liquid formulation of AMG 416 (etelcalcetide) |
Jun, 2034
(9 years from now) | |
| US11162500 | KAI PHARMS INC | Stable liquid formulation of AMG 416 (etelcalcetide) |
Jun, 2034
(9 years from now) | |
| US11959486 | KAI PHARMS INC | Stable liquid formulation of AMG 416 (etelcalcetide) |
Jun, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 07, 2022 |
Drugs and Companies using ETELCALCETIDE ingredient
NCE-1 date: 07 February, 2021
Market Authorisation Date: 07 February, 2017
Treatment: A method of treating secondary hyperparathyroidism (shpt)
Dosage: SOLUTION
How can I launch a generic of PARSABIV before it's drug patent expiration?
More Information on Dosage
PARSABIV family patents
